Active substanceCarbocysteineCarbocysteine Similar drugsTo uncover Bronhobos® capsules inwards Boznalek, AO Bosnia and Herzegovina Bronhobos® syrup inwards Boznalek, AO Bosnia and Herzegovina Libexin Muco® syrup inwards Sanofi-Aventis France France Libexin Muco® syrup inwards Sanofi-Aventis France France Fluviert syrup inwards Dompe Pharmacetici SpA Italy Fluviert granules inwards Dompe Pharmacetici SpA Italy Fluidite® syrup inwards Laboratory Innotech International France Fluidite® syrup inwards Laboratory Innotech International France Fluditik solution inwards Laboratory Innotech International France Dosage form: & nbspcapsules Composition:1 capsule contains: active substance: carbocysteine 375.0 mg; Excipients: corn starch - 23.00 mg, magnesium stearate - 2.00 mg, gelatin - 8.00 mg, silicon dioxide colloid - 2.00 mg. Description:Hard gelatinous opaque yellow No. 0 capsules filled with white powder. Pharmacotherapeutic group:Mucolytic agent ATX: & nbspR.05.C.B.03 Carbocysteine Pharmacodynamics:Mucolytic and expectorant action is due to the activation of sialic transferase - the enzyme of goblet cells of bronchial mucosa. Normalizes the quantitative ratio of acidic and neutral sialomucins to bronchial secretions.Reduces the viscosity of the bronchial secretion and the discharge from the paranasal sinuses, facilitates the passage of sputum and mucus, reduces cough. Promotes regeneration of the mucous membrane, normalizes its structure, activates the activity of the ciliary epithelium. Restores immunoglobulin secretion IgA (specific protection) and the amount of sulfhydryl groups of mucus components (nonspecific protection), improves mucociliary clearance. Pharmacokinetics:Carbocysteine is rapidly absorbed after oral administration. Bioavailability is low (less than 10% of the dose taken). The maximum concentration in the blood serum and in the mucous membrane of the respiratory tract is achieved 2-3 hours after taking the drug inside and remains in the mucosa for 8 hours. Metabolised in the liver (has the effect of "first pass" through the liver). It is excreted mainly by the kidneys, partly unchanged, partly in the form of metabolites. The elimination half-life is about 2 hours. Indications:Acute and chronic bronchopulmonary diseases, accompanied by the formation of viscous, hard to separate sputum (tracheitis, bronchitis, tracheobronchitis, bronchial asthma,bronchiectatic disease) and mucus (inflammatory diseases of the middle ear, nose and sinuses - rhinitis, otitis media, sinusitis), preparation for bronchoscopy and / or bronchography. Contraindications:Hypersensitivity to carbocysteine or other components of the drug, peptic ulcer of the stomach and duodenum in the acute stage, chronic glomerulonephritis (in the phase of exacerbation), cystitis, children under 15 years, pregnancy (I trimester). Carefully:When taking the drug with chronic glomerulonephritis (in the anamnesis), peptic ulcer of the stomach and duodenum (in the anamnesis), during pregnancy (II-III trimesters) and during lactation. Pregnancy and lactation:In the II and III trimesters of pregnancy, the drug is prescribed only if the intended benefit to the mother exceeds the potential risk to the fetus. If it is necessary to prescribe the drug during lactation, the question of stopping breastfeeding should be solved. Dosing and Administration:For oral administration. Adults and teenagers over 15 years of age: 750 mg (2 capsules) three times a day. After reaching the therapeutic effect, the daily dose is reduced to 1.5 g: 750 mg (2 capsules) twice a day. Treatment should not last more than 8-10 days without consulting a doctor. Side effects:From the gastrointestinal tract: sometimes there is nausea, vomiting, diarrhea, epigastric pain, gastrointestinal bleeding. Allergic reactions: itching, hives, exanthema, angioedema. Other: dizziness, weakness, malaise. Overdose:Symptoms: gastralgia, nausea, diarrhea. Treatment: symptomatic. Interaction:Carbocysteine increases the effectiveness of glucocorticosteroid and antibacterial therapy for inflammatory diseases of the upper and lower respiratory tract, potentiates the broncholytic effect of theophylline. Carbocisteine activity is weakened by antitussive and atropine-like agents. Special instructions:In patients with gastric ulcer and duodenal ulcer in history, the dose of the drug should be reduced. Treatment can be combined with physiotherapy procedures. Effect on the ability to drive transp. cf. and fur:The effect of the drug on the ability to drive vehicles and work that requires an increased concentration of attention and speed of psychomotor reactions has not been studied. Form release / dosage:Capsules of 375 mg. Packaging:10 capsules per blister PVC / AL.For 3 blisters with instructions for use in a cardboard box. Storage conditions:At a temperature of 15 ° to 30 ° C. Keep out of the reach of children. Shelf life:3 years. Do not use after expiry date. Terms of leave from pharmacies:Without recipe Registration number:LS-000081 Date of registration:25.02.2010 / 14.01.2013 Expiration Date:Unlimited The owner of the registration certificate:Boznalek, AOBoznalek, AO Bosnia and Herzegovina Manufacturer: & nbspBOSNALIJEK, d.d. Bosnia and Herzegovina Representation: & nbspBOSNALEK AO BOSNALEK AO Bosnia and Herzegovina Information update date: & nbsp07.03.2017 Illustrated instructions × Illustrated instructions Instructions